Fennec Pharmaceuticals (FENC) Gains from Investment Securities (2022 - 2025)

Fennec Pharmaceuticals' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $1000.0 for Q2 2025.

• Quarterly Gains from Investment Securities changed N/A year-over-year to $1000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $2000.0 (down 97.53% YoY) and the FY2025 annual result came in at $2000.0, down 97.53% from the prior year.
• Gains from Investment Securities was $1000.0 for Q2 2025 at Fennec Pharmaceuticals, roughly flat from $1000.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $67000.0 in Q4 2024 and bottomed at -$4000.0 in Q4 2023.
• A 4-year average of $20000.0 and a median of $11000.0 in 2024 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities plunged 106.9% — and 2024, when it jumped 1775.0%.
• Fennec Pharmaceuticals' Gains from Investment Securities stood at $58000.0 in 2022, then tumbled by 106.9% to -$4000.0 in 2023, then soared by 1775.0% to $67000.0 in 2024, then tumbled by 98.51% to $1000.0 in 2025.
• Business Quant data shows FENC's Gains from Investment Securities at $1000.0 in Q2 2025, $1000.0 in Q1 2025, and $67000.0 in Q4 2024.